Article
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase.
International journal of molecular sciences - 21 Apr 2015
Falvella Felicia Stefania, Caporale Marta, Cheli Stefania, Martinetti Antonia, Berenato Rosa, Maggi Claudia, Niger Monica, Ricchini Francesca, Bossi Ilaria, Di Bartolomeo Maria, Sottotetti Elisa, Bernardi Francesca Futura, de Braud Filippo, Clementi Emilio, Pietrantonio Filippo
Abstract excerpt
Fluoropyrimidines, the mainstay agents for the treatment of colorectal cancer, alone or as a part of combination therapies, cause severe adverse reactions in about 10%-30% of patients. Dihydropyrimidine dehydrogenase (DPD), a key enzyme in the catabolism of 5-fluorouracil, has been intensively investigated in relation to fluoropyrimidine toxicity, and several DPD gene (DPYD) polymorphisms are associated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.